GCC Syringes And Needles Market Analysis & Forecast: 2026-2033
The GCC Syringes and Needles Market is estimated to be valued at USD 762 Mn in 2026 and is expected to reach USD 1,087 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033.
The GCC syringes and needles market is advancing significantly with the rising applications in large-scale immunization programs, emergency care, and chronic disease management. Moreover, expanding consumer demand research for self-administration of therapeutics and tightening technical standards for safety-engineered devices designed to prevent needlestick injuries are expected to drive market growth over the forecast period.
The syringes and needles are essential drug delivery tools. They are mainly composed of high-purity medical-grade polymers or specialized glass. The manufacturing process is a regulated production technique and utilizes methods like precision injection molding and automated assembly to serve the hospital, diagnostic, and home care industries. This helps in the effective replacement of traditional reusable equipment with disposable single-use solutions in high-risk or high-volume clinical environments.
The GCC syringes and needles industry is entering a new era driven by advancing production factors, the adoption of advanced automated sterilization and high-precision needle grinding systems, along with high demand for injectable solutions in sectors such as diabetes care, biologics, and pediatric vaccinations. These developments have improved the capabilities of sterile delivery systems and enhanced their dosage accuracy, safety mechanisms, and cost efficiency. This marks a revolutionary phase in the market as it transitions from a volume-based commodity to a cornerstone of modern value-based healthcare and infection control.
|
Current Event |
Description and the Impact |
|
Technological Innovation and Manufacturing Advances |
|
|
Public Health Crises and Epidemiological Trends |
|
|
Geopolitical Stability and Regional Healthcare Policies |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of product type, the hypodermic segment contributes the highest share of 86.30% in 2026 of the GCC syringes and needles market. The growth is due to the escalating prevalence of chronic diseases like diabetes and cardiovascular conditions. These illnesses require frequent, precise drug delivery through subcutaneous and intramuscular routes, which hypodermic needles facilitate effectively. In addition, the regional government initiatives focused on mass immunization and the expansion of primary healthcare infrastructure are boosting the demand for these products. The segment is also experiencing a shift toward safety-engineered designs to adhere to the international standards. This ensures that the healthcare providers can deliver high volumes of medication as well as minimize the risk of needlestick injuries.
In terms of usability, the disposable segment contributes the highest share of 80.10% in 2026 of the GCC syringes and needles market as GCC nations place greater emphasis on strict infection control and patient safety mandates. By utilizing single-use pre-sterilized syringes, healthcare facilities can greatly reduce the transmission of bloodborne pathogens such as HIV and Hepatitis B. The increase of home healthcare and self-administration of therapies like insulin further drives this segment, as patients prefer the convenience and assured sterility of disposable formats. In addition, the local regulatory frameworks mandate the use of auto-disable and safety-engineered disposable devices to protect both patients and medical staff. This strengthens the segment's role as the main choice across the region.
In terms of material, the polymer segment contributes the highest share of 61.90% in 2026 of the GCC syringes and needles market as it is favored for its high shatter resistance and lower cost compared to traditional glass. Materials such as polypropylene are frequently used because they are lightweight, chemically inert, and compatible with multiple sterilization techniques, making them well-suited for mass-produced medical disposables. The flexibility of polymers allows for the design of complex features such as those found in pre-filled and safety-retractable syringes. They are gaining popularity in the UAE and Saudi Arabia. The ease of polymer processing supports high-speed production lines as the GCC expands somatic medical manufacturing. This ensures a steady and cost-effective supply of essential medical devices.
The Kingdom of Saudi Arabia has remained the dominant country with 71.40% in 2026 of the global GCC syringes and needles market over the past decade. The growth is mainly driven by the wide healthcare transformation goals set in its national developmental strategy. As the government spends heavily on growing hospital capacity and primary care centers, the volume of medical consumables required keeps rising. The market's size is further supported by a large population and a high prevalence of chronic conditions that require long-term injectable therapies. Furthermore, the Kingdom is actively encouraging domestic manufacturing of medical devices to ensure a stable supply chain and reduce dependence on imports. This shift toward local production, together with strict safety rules for engineered needles, helps strengthen Saudi Arabia’s position as the main hub for medical procurement in the Gulf.
The UAE is recognized as the fastest-growing market for syringes and needles in the region, driven by its reputation as a global hub for medical tourism. The country’s rapid growth of private specialty clinics and a well-developed health insurance system help a steady rise in demand for advanced drug delivery systems. Unlike other systems, the UAE shows a quicker preference for premium, innovative products such as pre-filled syringes and safety retractable needles to serve a tech-savvy patient base. This growth is also fueled by a strong healthcare infrastructure and a strategic focus on using modern medical technologies in everyday care. In addition, the UAE’s role as an important logistics and re-export hub ensures that the newest medical innovations are quickly adopted and shared across its expanding network of facilities.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 762 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.2% | 2033 Value Projection: | USD 1,087 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Becton, Dickinson and Company, Nipro Corporation, Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Medtronic plc., Smiths Group plc., Abu Dhabi Medical Devices Company, IMN Sina Medical Factory, Alshifa Medical Syringes Manufacturing Company Limited, International Korean Medical Company, Mais Saudia, and VITREX Medical A/S |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases is driving up the demand for syringes and needles used in the diagnosis and treatment of these conditions. This trend is expected to contribute to the growth of the syringes and needles market over the forecast period. For example, an article published by the International Diabetes Federation (IDF) in December 2021 reported that 73 million adults were living with diabetes in the IDF Middle East and North Africa (MENA) region in 2021. This number is projected to rise to 95 million by 2030 and reach 136 million by 2045 in the MENA region.
The increased efforts by key players in the country, including investments in the manufacturing of medical equipment for global export, are expected to drive market growth in the region over the forecast period. For instance, in October 2022, the U.A.E. invested USD 70 million in medical equipment manufacturing as well as the global export initiatives. As part of this effort, PureHealth, a healthcare provider in the UAE, partnered with the Abu Dhabi Medical Devices Company (ADMD), Abu Dhabi Ports Group, and polymers supplier Borouge to create a medical supplies production line in Abu Dhabi.
Currently at the memorandum of understanding (MoU) stage, this initiative will have Borouge, a joint venture between the Abu Dhabi National Oil Company (Adnoc) and the Austria-based Borealis, supply the raw materials. Meanwhile, Abu Dhabi Ports Group, which serves as the region's premier facilitator of logistics, industry, and trade, will provide the industrial land necessary to establish a factory for producing syringes, administration devices, and blood collection tubes. In a separate agreement, PureHealth and pharmaceutical company Julphar will establish the first factory in the Middle East dedicated to producing Glargine, a long-acting biological alternative to insulin used in diabetes treatment.
The GCC syringes and needles market covers the trade and use of sterile medical delivery devices across the Gulf Cooperation Council nations, including Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Oman, and Bahrain. The sector includes product types such as disposable hypodermic needles, insulin syringes, and advanced safety devices designed to reduce needlestick injuries. The market growth is owing to the growth in the healthcare infrastructure, government vaccination efforts, and the rising number of chronic diseases requiring regular injections. The industry is moving toward high-quality plastic materials and prefilled systems in order to improve patient safety and clinical efficiency. The market also supports hospitals, diagnostic centers, and the growing home care segment as the government promotes local medical manufacturing.
Share
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
